

Index

- A**
- Abl, kinase modulation by SH2
allosteric activation, 39–40
inhibition by intramolecular interactions, 38–39
- Acetylcholine receptor (AChR)
muscle-specific kinase interactions, 265–268
myasthenia gravis autoantibodies, 271–272
- AChR. *See* Acetylcholine receptor
- Acute myeloid leukemia, Kit role, 217
- ADAM proteases
domain structure, 119–120
ephrin cleavage, 312
epidermal growth factor receptor ligand
shedding role, 120–121
shedding
stimuli, 121–122
tetraspanins in spatial control, 122–123
- ADAM10
ephrin proteolysis, 126
platelet-derived growth factor receptor
ligand proteolysis, 126
- ADAM12, ErbB2 expression regulation, 140
- ADAM17 (TACE)
activity regulation in plasma membrane, 122
ErbB-4 as substrate, 50–51, 68–69
trafficking regulators, 123
- Agrin, Lrp4 binding, 265, 269–270
- Akt
ephrin receptor signaling, 310–311
Grb2 in signaling, 38
insulin receptor signaling, 412–413
insulin resistance defects, 420
MET signaling, 437
RET signaling, 280–281
TAM receptor signaling, 371
- Alk. *See* Anaplastic lymphoma kinase
- α -Secretase. *See* ADAM17
- AMSH, endosomal sorting role, 86
- Amyotrophic lateral sclerosis, ephA4 mutations, 317
- Anaplastic lymphoma kinase (Alk)
Drosophila function, 347–349
therapeutic targeting, 18
- Angiogenesis. *See also* Angiopoietins; Vascular endothelial growth factor receptor
Ang2 signals in inflammation, 395–396
blood versus lymphatic vasculature, 388–389
cancer
endothelial cell-derived tumors, 396
metastasis studies, 394
tumor vascularization, 393–394
development
endothelial cell expression of receptors
Tie receptors, 392–393
vascular endothelial growth factor
receptor, 391–392
overview, 387–388
inhibition for therapy, 396–400
lymphangiogenesis defects in lymphedema, 375
prospects for study, 400
therapeutic angiogenesis, 394–395
tip and stalk cell expression of receptor
tyrosine kinases, 389
vascular malformations, 396
- Angiopoietins
Ang2 signals in inflammation, 395–396
angiogenesis role, 391
functional overview, 287–288
inhibitor therapy, 399–400
knockout mouse, 392–393
structure, 288–289
vascular endothelial growth factor receptor
signaling cross talk, 234
- Apoptosis, TAM receptors in cell clearance, 373–374
- Atherosclerosis, platelet-derived growth factor
receptor role, 214
- Axl. *See* TAM receptors
- B**
- BCR-ABL
chronic myelogenous leukemia, 17–18
therapeutic targeting, 18
- Bevacizumab, 235
- Bioinformatics, tyrosine phosphorylation, 23
- Breast cancer, RET mutations, 461
- Breathless, *Drosophila* studies, 343–344
- BY kinases, features, 19
- C**
- Cad96Ca, *Drosophila* wound repair, 353
- Cancer
angiogenesis
endothelial cell-derived tumors, 396

Index

- Cancer (*Continued*)
 metastasis studies, 394
 tumor vascularization, 393–394
 ephrin receptor mutations, 316–317
 Kit role
 acute myeloid leukemia, 217
 gastrointestinal stromal tumor, 217
 lung cancer, 217–218
 melanoma, 217
 ligand shedding dysregulation, 126–127
 lung cancer epidermal growth factor receptor
 mutations and therapeutic targeting,
 166, 168
 MET therapeutic targeting in cancer, 443–444
 platelet-derived growth factor receptor tumor cell
 overactivity, 213–214
 RET mutations. *See* RET
 Ror studies, 328
 TAM receptor defects, 378–379
 Caspases, intracellular domain cleavage from receptor
 tyrosine kinases, 55
 Cbl
 MET signaling, 439
 mutation in cancer, 42
 receptor endocytosis role, 82–83
 SH2 domain, 35
 Ceramide, insulin resistance role, 420
 Clathrin-mediated endocytosis. *See* Endocytosis,
 receptor tyrosine kinases
 CMS. *See* Congenital myasthenic syndrome
 Colony-stimulating factor-1 receptor, intracellular
 domain cleavage by γ -secretase, 53–54
 Congenital myasthenic syndrome (CMS), gene
 mutations, 42
 Crizotinib, receptor tyrosine kinase inhibition, 18
 Crk
 ephrin receptor signaling, 308
 platelet-derived growth factor receptor
 binding, 210
 SH2/SH3 domains, 9
 signaling complex assembly, 38
 Cryoelectron microscopy, phosphotyrosine protein
 structure, 22, 26

D
 DAG. *See* Diacylglycerol
 DC. *See* Dendritic cell
 DDR. *See* Discoid domain receptor
 Degenerate peptide library, tyrosine kinase target
 identification, 22–23
 Dendritic cell (DC), TAM receptor function, 375–376
 Derailed
 Drosophila studies, 351–352
 Wnt signaling, 330–332
 Derailed 2, *Drosophila* studies, 352–353

 Diabetes. *See* Insulin resistance
 Diacylglycerol (DAG), insulin resistance role, 420
 Discoid domain receptor (DDR),
 Drosophila studies, 350
 Dok-2, PTB domain, 37
 Dok-7, 42, 270–272
 Doughnut, *Drosophila* studies, 352
Drosophila
 anaplastic lymphoma kinase function, 347–349
 Cad96Ca in wound repair, 353
 discoid domain receptor function, 350
 ephrin receptor function, 354
 epidermal growth factor receptor
 functional overview, 341–342
 ligand proteolysis
 overview, 116–117
 trafficking regulation, 117–118
 fibroblast growth factor receptors
 Breathless, 343–345
 Heartless, 342–343
 insulin receptor function, 345–347
 neurotrophic receptor kinase function, 349
 Offtrack function, 350–351
 overview of receptor tyrosine kinases and ligands,
 337–339
 prospects for receptor tyrosine kinase studies,
 356–357
 Pvr function, 354–356
 RET function, 353
 rhomboids, 116–117, 125
 Ror function, 326, 349
 Ryk receptors
 Derailed, 351–352
 Derailed 2, 352–353
 Doughnut, 352
 Sevenless in cell fate specification in eye and testes,
 340–341
 Tie-like receptor tyrosine kinase function, 356
 Torso role in anterior/posterior patterning and
 metamorphosis, 339–340
 DUSP, 141

E
 EGFR. *See* Epidermal growth factor receptor
 Endocytosis, receptor tyrosine kinases
 clathrin-independent endocytosis, 79–80
 clathrin-mediated endocytosis, 79
 cytoplasmic domain sequence motifs, 80
 endosomal sorting. *See* Endosomal sorting,
 receptor tyrosine kinases
 half-life range, 77
 miscellaneous mechanisms, 84
 NEDD4 role, 83–84
 pathways, 78–80
 prospects for study, 88

- receptor ubiquitination role, 80–83
- signaling effects
 - cell adhesion regulators, 100
 - hypoxia modulation, 99–100
 - ligand concentration effects on entry routes and intracellular fate, 97–99
 - overview, 95–97
 - spatial regulation of internalization, 100–101
 - stress factor modulation, 99
- steps, 77–79
- ubiquitin-binding proteins in CCPs, 84
- Endoplasmic reticulum (ER)
 - receptor tyrosine kinase signal modulation, 107–108
 - unfolded protein response in insulin resistance, 422
- Endosomal sorting, receptor tyrosine kinases
 - coreceptor-modulated sorting of ligand–receptor complexes, 103
 - ESCRT sorting model, 85–86
 - ligand-dependent sorting of receptor, 101–102
 - multivesicular body sorting model, 85–87
 - overview, 85
 - receptor-mediated sorting of ligands, 102–103
 - recycling of receptors. *See* Recycling, receptor tyrosine kinases
 - signaling effects
 - compartmentalization of signaling, 107
 - endoplasmic reticulum in signal modulation, 107–108
 - intracellular signal delivery via endosomes, 105
 - microvesicle propagation of signals, 108
 - signal amplification, 105–107
 - signaling endosomes, 105
- Ephrin, proteolysis, 126, 298–299, 313
- Ephrin receptor
 - angiogenesis role, 388
 - Drosophila* studies, 354
- Ephrin receptor
 - activation
 - kinase, 297–298
 - transmembrane domain role, 297
 - classification, 305
 - clustering and activation, 296–298, 307
 - dephosphorylation, 315
 - ephrin-independent activities, 314–315
 - functional overview, 292–294, 305–306
 - internalization and proteolysis, 312–314
 - intracellular domain cleavage by γ -secretase, 53
 - ligand recognition and binding, 294–295
 - mutation and disease, 316–317
 - prospects for study, 299, 317
 - signaling
 - ephrin-mediated *cis* attenuation, 314
 - forward signaling, 306–311
 - reverse signaling, 311–312
 - termination, 298–299
 - structure, 305–306
 - therapeutic targeting, 295
- Epidermal growth factor receptor (EGFR).
 - See also specific receptors*
 - dimerization, 5–8
 - endocytosis, 79–84, 99–100
 - endosomal sorting, 87
 - family characteristics, 161–163
 - history of study, 1, 3–5, 15, 17–18
 - kinase domain activation, 164, 166–167
 - ligand concentration effects on entry routes and intracellular fate, 97–98
 - ligand proteolysis
 - ADAMs in ligand shedding, 120–121
 - Drosophila*
 - overview, 116–117
 - trafficking regulation, 117–118
 - mammalian ligands, 118–119
 - ligand-dependent sorting, 101–102
 - linkage between intracellular and extracellular regions, 172–173
 - lung cancer mutations and therapeutic targeting, 166, 168
 - negative cooperativity, 171–173
 - phospholipase C γ association, 9
 - phosphorylation sites, 9
 - recycling, 87–88
 - signaling
 - cross talk, 9–10, 134–137, 142–143
 - feedforward loops, 137–138
 - positive and negative feedback regulation
 - overview, 138–139
 - receptor level, 139–140
 - signaling level, 140
 - transcription, 140–142
 - prospects for study, 144–145
 - spatial signal propagation, 143–144
 - transduction, 179, 181
- ER. *See* Endoplasmic reticulum
- ErbB receptors
 - kinase domain activation, 164, 166–167
 - ligands
 - receptor dimerization induction, 164–165
 - types and processing, 163–164
 - linkage between intracellular and extracellular regions, 172–173
 - lung cancer mutations and therapeutic targeting, 166, 168
 - negative cooperativity, 171–173
 - plasma membrane distribution, 193–197
 - spatiotemporal organization
 - cluster size studies with conventional microscopy, 181–182
 - fluorescence resonance energy transfer
 - activation and signaling, 188–189
 - protein–protein interactions, 184–186
 - high-resolution imaging, 182–184

Index

- ErbB receptors (*Continued*)
- prospects for study, 189
 - single-molecule studies of protein–protein interactions, 186–188
 - techniques for study, 179–180
 - structure
 - carboxy-terminal tail, 170–171
 - extracellular juxtamembrane region, 168–169
 - intracellular juxtamembrane region, 169–170
 - transmembrane domain, 168
- ErbB1
- nuclear trafficking and function, 56–57, 73
 - plasma membrane distribution, 195
 - signaling
 - filopodia, 198–200
 - potentiation, 200–201
 - without ligand, 20
 - splicing-dependent fragments, 56
 - structure, 181, 197–199
- ErbB2
- carboxy-terminal fragment cleavage, 55–56
 - nuclear trafficking and function, 57–58, 71
 - plasma membrane distribution, 195–196
 - therapeutic targeting, 18
- ErbB3
- nuclear trafficking and function, 57–58, 71–72
 - plasma membrane distribution, 196
- ErbB4
- intracellular domain cleavage by γ -secretase, 50–53
 - nuclear signaling, 68–70
- Erlotinib, lung cancer management, 166
- ESCRT, endosomal sorting model, 85–87
- Evolution
- protein tyrosine phosphatases, 21
 - receptor tyrosine kinases, 20–21
 - tyrosine kinases, 19–20
- F**
- FGF. *See* Fibroblast growth factor
- FGFR. *See* Fibroblast growth factor receptor
- FGFR1. *See* Fibroblast growth factor receptor 1
- FGFR2. *See* Fibroblast growth factor receptor 2
- FGFR3. *See* Fibroblast growth factor receptor 3
- FGFR4. *See* Fibroblast growth factor receptor 4
- Fibroblast growth factor (FGF)
- receptor ligand-binding specificity mechanisms
 - FGF1 subfamily, 247–249
 - FGF7 subfamily, 247
 - FGF8 subfamily, 249–250
 - structure–function relationships, 242–243
 - types, 242
- Fibroblast growth factor receptor (FGFR)
- alternative splicing
 - D1 and D1–D2 linker and receptor autoinhibition, 252–253
 - D3 and ligand specificity, 246–247
 - dimerization, 8
 - Drosophila*
 - Breathless, 343–345
 - Heartless, 342–343
 - heparan sulfate binding, 250–252
 - kinase
 - autophosphorylation, 255–257
 - regulation mechanism, 253–255
 - Klotho in signaling, 252–253
 - ligand–receptor contacts, 246
 - prospects for study, 257
 - structure, 242–246
- Fibroblast growth factor receptor 1 (FGFR1)
- endosomal signaling, 107
 - intracellular domain cleavage by granzyme B, 55
 - ligand-dependent sorting, 102
 - nuclear trafficking and function, 59, 74
- Fibroblast growth factor receptor 2 (FGFR2)
- ligand-dependent sorting, 102
 - nuclear trafficking, 59
- Fibroblast growth factor receptor 3 (FGFR3), intracellular domain cleavage by γ -secretase, 55
- Fibroblast growth factor receptor 4 (FGFR4), receptor-mediated sorting of ligand, 103
- Fibroblast growth factor receptor substrate 2 (FRS2)
- PTB domain, 37
 - recruitment and activation of signaling molecules, 10
- Flt-1. *See* Vascular endothelial growth factor receptor
- Fluorescence resonance energy transfer (FRET)
- ErbB receptor
 - activation and signaling, 188–189
 - protein–protein interactions, 184–186, 197–199
 - kinase assays, 23–24
 - subcellular localization of tyrosine phosphorylation, 25
- Foxo1, insulin receptor signaling, 413
- FRET. *See* Fluorescence resonance energy transfer
- Frizzled, Wnt ligands, 325–326
- FRS2. *See* Fibroblast growth factor receptor substrate 2
- G**
- Gab1, MET signaling, 436–437
- γ -Secretase, intracellular domain cleavage from receptor tyrosine kinases
- colony-stimulating factor-1 receptor, 53–54
- Ephrin-B2 receptor, 53
- ErbB-4, 50–53
- fibroblast growth factor receptor 3, 55
- insulin receptor, 54

insulin-like growth factor-1 receptor, 54
Met, 55
overview, 49–51
protein tyrosine kinase 7, 55
Ryk, 54–55
Tie1, 54
vascular endothelial growth factor receptor, 54
GAPs. *See* GTPase-activating proteins
Gas6, TAM receptor binding, 371, 373, 377
Gastrointestinal stromal tumor, Kit role, 217
Gefitinib, lung cancer management, 166
GEFs. *See* Guanine nucleotide exchange factors
Genetic screens, tyrosine phosphorylation, 24–25
GGA3, receptor tyrosine kinase sorting role, 104
Glial-derived neurotrophic factor (GDNF), RET
binding, 278
Granzyme B, intracellular domain cleavage from
receptor tyrosine kinases, 56
Grb2
insulin receptor signaling, 414
MET signaling, 438
receptor endocytosis role, 83
recruitment, 30–31, 37–38
RET signaling, 281
SH2 domain, 9, 33, 37
SH3 domains, 9, 38
Sprouty binding, 141
Grb10
insulin action modulation, 416
insulin receptor regulation, 156–157
Grb14
insulin action modulation, 416
insulin receptor regulation, 155–157
GTPase-activating proteins (GAPs)
ephrin receptor signaling, 308
receptor tyrosine kinase spatial signal
propagation, 143–144
Guanine nucleotide exchange factors (GEFs)
ephrin receptor signaling, 308
receptor tyrosine kinase spatial signal
propagation, 143–144

H

Heartless, *Drosophila* studies, 342–343
Hematopoiesis, Kit role, 216
Heparan sulfate (HS), fibroblast growth factor
receptor binding, 250–252
Hepatocyte growth factor receptor. *See* MET
HER2. *See* ErbB2
Herceptin, receptor tyrosine kinase inhibition, 18
Heregulins, ErbB receptor binding, 163
Hirschsprung's disease, RET mutations, 282
HS. *See* Heparan sulfate
Hypoxia, receptor tyrosine kinase endocytosis
effects, 99–100

I

ICD. *See* Intracellular domain
IGF-1R. *See* Insulin-like growth factor-1 receptor
Imatinib, receptor tyrosine kinase inhibition, 18
Insulin-like growth factor-1 receptor (IGF-1R)
endosomal sorting, 87
intracellular domain cleavage by γ -secretase, 54
nuclear trafficking, 58, 73–74
structure, 409–410
substrates, 411
ubiquitination and endocytosis, 83–84
Insulin receptor
activation, 151–152
Drosophila studies, 345–347
endocytosis, 80
history of study, 1, 3
insulin resistance defects, 418
intracellular domain cleavage by γ -secretase, 54
kinase domain regulation, 152–153
negative regulator recruitment, 155–157
negative regulators
Grb10, 416
Grb14, 416
lipid phosphatases, 415–416
protein phosphatases, 414–415
serine/threonine phosphorylation, 416–418
suppressor of cytokine signaling, 416
Trb3, 416
prospects for study, 157–158
recycling, 87
signaling
3-phosphoinositide-dependent protein
kinase 1, 412–414
Akt, 412–413
Foxo1, 413
Grb2, 414
mitogen-activated protein kinase, 414
mTORC1, 413
nitric oxide, 413
phosphatidylinositol 3-kinase, 411–412
protein kinase C, 414
protein recruitment, 153–155
Ras, 414
structure
membrane topology, 150
overview, 409–410
subunits, 149–150
three-dimensional structure, 150–151
substrates, 411
Insulin receptor substrate 1 (IRS1)
insulin resistance defects, 418
knockout mouse, 411
PTB domain, 37
recruitment and activation of signaling
molecules, 10, 153–154
Insulin receptor substrate 2 (IRS2), recruitment, 154

Index

- Insulin receptor substrate 3 (IRS3),
tissue distribution, 411
- Insulin receptor substrate 4 (IRS4),
tissue distribution, 411
- Insulin resistance
gene defects
Akt, 420
insulin receptor, 418
insulin receptor substrate 1, 418
phosphatidylinositol 3-kinase, 418
PTEN, 419
hyperglycemia mechanisms, 421
lipotoxicity, 420
mitochondrial dysfunction, 421–422
obesity-associated inflammation, 421
prospects for study, 422
unfolded protein response, 422
- Internalization. *See* Endocytosis, receptor
tyrosine kinases
- Intracellular domain (ICD)
caspase cleavage from receptor tyrosine kinases, 55
 γ -secretase cleavage from receptor tyrosine kinases
colony-stimulating factor-1 receptor, 53–54
Ephrin-B2 receptor, 53
ErbB-4, 50–53
fibroblast growth factor receptor 3, 55
insulin receptor, 54
insulin-like growth factor-1 receptor, 54
Met, 55
overview, 49–51
protein tyrosine kinase 7, 55
Ryk, 54–55
Tie1, 54
vascular endothelial growth factor receptor, 54
granzyme B cleavage from receptor
tyrosine kinases, 56
prospects for study, 59
rhomboid-dependent fragments, 56
- iRhoms. *See* Rhomboids
- IRS1. *See* Insulin receptor substrate 1
- IRS2. *See* Insulin receptor substrate 2
- IRS3. *See* Insulin receptor substrate 3
- IRS4. *See* Insulin receptor substrate 4
- J**
- JAK, TAM receptor signaling, 371
- K**
- Kinome, human, 16
- Kit
diseases
acute myeloid leukemia, 217
gastrointestinal stromal tumor, 217
lung cancer, 217–218
mastocytosis, 217
melanoma, 217
piebaldism, 218
down-regulation, 216
functions
fertility, 217
hematopoiesis, 216
neurons, 217
peristalsis, 217
pigmentation, 216–217
ligand dimers, 8
phosphorylation sites, 9
prospects for study, 218
signaling, 215–216
stem cell factor activation, 215
- KLF2, 141–142
- Klotho, fibroblast growth factor receptor signaling,
252–253
- L**
- Leukemia, RET mutations, 460–461
- Ligand shedding. *See also specific ligands and receptors*
ADAM proteases, 119–123
cancer dysregulation, 126–127
Drosophila studies, 116–118
ephrins, 126
epidermal growth factor receptor ligands, 118–119
rhomboids, 123–125
- lin-18, Wnt signaling, 330–332
- LRIG1, 140–141
- LRP1, ephrin receptor association, 314–315
- Lrp4
Agrin binding, 265, 269–270
myasthenia gravis autoantibodies, 271–272
neuromuscular synapse formation role, 265–268
structure and function, 269–270
- LRP5, Wnt ligands, 325–326
- LRP6
ligand concentration effects on entry routes and
intracellular fate, 98–99
Wnt ligands, 325–326
- Lung cancer
epidermal growth factor receptor mutations and
therapeutic targeting, 166, 168
Kit role, 217–218
RET mutations, 460
- Lymphangiogenesis. *See* Angiogenesis
- Lymphedema, lymphangiogenesis defects, 375
- M**
- MAPK. *See* Mitogen-activated protein kinase
- Mass spectrometry (MS)
kinase assays, 23–24
phosphotyrosine proteomics, 22

- Mastocytosis, Kit role, 217
Medullary thyroid carcinoma (MTC),
RET mutation, 458–459
Melanoma, Kit role, 217
MEN2. *See* Multiple endocrine neoplasia type 2
Mer. *See* TAM receptors
MET
activation
ligand induction, 436
mutational activation, 439–441
functional overview, 433–434
history of study, 433–434
intracellular domain cleavage by γ -secretase, 55
knockout and transgenic mouse studies, 441–443
nuclear trafficking, 59
prospects for study, 444–445
signaling
Akt, 437
Cbl, 439
Gab1, 436–437
Grb2, 438
mitogen-activated protein kinase, 437–438
phosphatidylinositol 3-kinase, 437–438
Ras, 437–438
STAT3, 438
termination, 438–439
sorting proteins, 103–104
structure
hepatocyte growth factor ligand, 434–435
receptor, 434–436
therapeutic targeting in cancer, 443–444
Metabolic syndrome. *See* Insulin resistance
MG. *See* Myasthenia gravis
Mig-6, 141
Milestones, receptor tyrosine kinase studies, 2
Mitogen-activated protein kinase (MAPK)
insulin receptor signaling, 414
MET signaling, 437–438
receptor tyrosine kinase
endocytosis induction, 99
signaling cross-talk, 9–10, 134–137, 142–143
RET signaling, 280–281
TAM receptor signaling, 371
MS. *See* Mass spectrometry; Multiple sclerosis
MTC. *See* Medullary thyroid carcinoma
mTORC1, insulin receptor signaling, 413
Multiple endocrine neoplasia type 2 (MEN2),
RET mutations, 457–458
Multiple sclerosis (MS), TAM receptor defects, 377
Multivesicular body (MVB), receptor tyrosine kinase
sorting, 85–87
Muscle-specific kinase (MuSK)
functional overview, 265–266, 272
myasthenia gravis autoantibodies, 271–272
neuromuscular synapse formation role, 266–268
prospects for study, 272–273
signaling, 270–271
structure
extracellular region, 268
intracellular region, 268–269
MuSK. *See* Muscle-specific kinase
MvB. *See* Multivesicular body
Myasthenia gravis (MG), autoantibodies, 271–272
- N**
Nck
ephrin receptor signaling, 308
platelet-derived growth factor receptor binding, 210
SH2/SH3 domains, 9
NEDD4, receptor endocytosis role, 83–84
Neurotrophic receptor kinase (Nrk), *Drosophila*
function, 349
Nitric oxide (NO), insulin receptor signaling, 413
NMDA receptor, ephrin receptor phosphorylation,
312–313
NMR. *See* Nuclear magnetic resonance
NO. *See* Nitric oxide
Noonan syndrome, Shp2 defects, 42–43
Nrk. *See* Neurotrophic receptor kinase
Nuclear magnetic resonance (NMR), phosphotyrosine
protein structure, 22, 26
- O**
Offtrack (Otk), *Drosophila* studies, 350–351
Otk. *See* Offtrack
- P**
p38 mitogen-activated protein kinase. *See* Mitogen-
activated protein kinase
Pancreatic cancer, RET mutations, 461
Papillary thyroid carcinoma (PTC), RET defects
fusion partners of *RET*, 456
oncogenes, 453
RET/PTC
formation mechanisms, 455
oncogenic activation mechanisms, 455–456
oncogenic activity, 454–455
prevalence, 453–454
PCP. *See* Planar cell polarity
PDGFR. *See* Platelet-derived growth factor receptor
PDK-1. *See* 3-Phosphoinositide-dependent protein
kinase 1
PDZ domain, ephrin receptor signaling, 311
Peristalsis, Kit role, 217
Phosphatidylinositol 3-kinase (PI3K)
Grb2 in signaling, 38
insulin receptor signaling, 411–412
insulin resistance defects, 418
MET signaling, 437–438

Index

- Phosphatidylinositol 3-kinase (PI3K) (*Continued*)
 RET signaling, 280–281
 TAM receptor signaling, 371
- Phosphatidylserine, TAM receptor signaling role,
 371, 373
- 3-Phosphoinositide-dependent protein kinase 1
 (PDK-1), insulin receptor signaling,
 412–414
- Phospholipase C γ (PLC γ)
 epidermal growth factor receptor association, 9
 RET signaling, 280–281
 SH2-mediated assembly, 41–42
 vascular endothelial growth factor receptor
 signaling, 232–234
- Phosphotyrosine (P.Tyr)
 abundance, 18–19
 chemical properties, 19
 detection, 23–24
- PI3K. *See* Phosphatidylinositol 3-kinase
- Piebaldism, Kit role, 218
- Pigmentation, Kit role, 216–217
- PKA. *See* Protein kinase A
- PKC. *See* Protein kinase C
- Planar cell polarity (PCP), Ror role, 330
- Platelet-derived growth factor receptor (PDGFR)
 activation, 209–210
 angiogenesis role, 388
 dimerization, 5
 disease processes
 atherosclerosis, 214
 fibrosis, 214
 therapeutic targeting, 214–215
 tumor cell overactivity, 213–214
 virus binding, 214
 embryo development function, 211–212
 history of study, 2, 4, 17
 internalization and sorting, 211
 ligand concentration effects on entry routes
 and intracellular fate, 97–98
 ligand shedding, 126
 ligands
 binding specificity, 208–209
 dimers, 8
 phosphorylation sites, 9
 signaling
 activation of pathways, 210–211
 modulation, 211
 ubiquitination, 80
 wound healing role, 212–213
- PLC γ . *See* Phospholipase C γ
- Preeclampsia, sFlt-1 role, 232
- Presenilin, substrate recognition, 51–52, 69
- PRK7. *See* Protein tyrosine kinase 7
- Prosl, TAM receptor binding, 371, 373, 377
- Protein kinase A (PKA), RET signaling, 281
- Protein kinase C (PKC)
 insulin receptor signaling, 414
 receptor tyrosine kinase
 endocytosis induction, 99
 sorting role, 104
 vascular endothelial growth factor receptor
 signaling, 232–234
- Protein tyrosine kinase 7 (PRK7), intracellular domain
 cleavage by γ -secretase, 55
- PTB domain
 classification of proteins, 37
 diversity of proteins, 31–32
 functions, 37
 insulin receptor substrates, 153–154
 phosphotyrosine binding
 binding modes, 36–37
 recognition, 30–31
 signaling in disease, 42
 structure of binding domains, 36
 recruitment of proteins by activated receptor
 tyrosine kinases, 17
- PTC. *See* Papillary thyroid carcinoma
- PTEN
 insulin action modulation, 415
 insulin resistance defects, 419
- PTP1B, insulin receptor regulation, 155–157
- P.Tyr. *See* Phosphotyrosine
- Pvr, *Drosophila* studies, 354–356
- R**
- RA. *See* Rheumatoid arthritis
- Ragulator complex, 107
- RALT/Mig-6, receptor endocytosis role, 84
- Rapsyn, 270–272
- Ras
 ephrin receptor signaling, 310, 314
 insulin receptor signaling, 414
 MET signaling, 437–438
 receptor tyrosine kinase signaling cross-talk, 9–10
 RET signaling, 280–281
- Reactive oxygen species (ROS), insulin resistance role,
 421–422
- Recycling, receptor tyrosine kinases
 degradation versus recycling signals
 receptor tyrosine kinase-based sorting
 signals, 103–104
 sorting proteins, 104–105
 mechanisms, 87–88
- RET
 activation, 451–452
 breast cancer mutations, 461
 coreceptors, 278
Drosophila studies, 353
 evolution, 278–279
 functional overview, 452–453
 gain-and loss-of-function mutations, 459–460

- inhibitors, 461
 - kidney development role, 281–282
 - leukemia mutations, 460–461
 - ligands, 278, 452
 - lung cancer mutations, 460
 - medullary thyroid carcinoma mutation, 458–459
 - multiple endocrine neoplasia type 2 mutations, 457–458
 - mutation and disease, 278
 - nervous system development role
 - enteric nervous system, 282
 - motoneurons, 282
 - ventral midbrain dopaminergic neurons, 282–283
 - pancreatic cancer mutations, 461
 - papillary thyroid carcinoma
 - fusion partners of *RET*, 456
 - oncogenes, 453
 - RET/PTC*
 - formation mechanisms, 455
 - oncogenic activation mechanisms, 455–456
 - oncogenic activity, 454–455
 - prevalence, 453–454
 - point mutations and oncogenesis, 459
 - prospects for study, 283
 - signaling, 280–281
 - structure, 277–278, 451
 - structure–function studies, 279–280
 - therapeutic targeting, 461–462
 - tissue distribution, 453
- RHBDL2, 215
- Rheumatoid arthritis (RA), TAM receptor
 - defects, 375, 377
- Rho, ephrin receptor signaling, 308–310
- Rhomboids
 - domain structure, 116–117
 - Drosophila*, 116–117, 125
 - mammals
 - iRhoms, 123–125
 - types, 125
- RIN1, receptor endocytosis role, 84
- RKIP, 140
- Ron, nuclear trafficking, 58–59
- Ror
 - cancer role, 328
 - developmental function
 - invertebrates and amphibians, 326, 349
 - mammals, 327–328
 - history of study, 326
 - prospects for study, 332
 - signaling, 328–330
- ROS. *See* Reactive oxygen species
- Ryk
 - Drosophila* studies
 - Derailed, 351–352
 - Derailed 2, 352–353
 - Doughnut, 352
 - intracellular domain cleavage by γ -secretase, 54–55
 - nuclear signaling, 70
 - prospects for study, 332
 - Wnt signaling, 70, 330–332
- S**
- Sec61, nuclear trafficking of receptor tyrosine kinases, 57–58
- Sevenless, cell fate specification in eye and testes, 340–341
- SH2 domain
 - Crk signaling complex assembly, 38
 - diversity of proteins, 31–32
 - insulin receptor-interacting proteins, 154–156
 - kinase allosteric activation, 39–40
 - kinase inhibition by intramolecular interactions, 38–39
 - overview, 9
 - phospholipase C γ assembly mediation, 41–42
 - phosphotyrosine binding
 - canonical binding, 33–35
 - noncanonical binding, 35
 - recognition, 30–31, 33
 - signaling in disease, 42–43
 - prospects for study, 43
 - receptor tyrosine kinase adapter proteins, 9
 - recruitment of proteins by activated receptor tyrosine kinases, 17
 - Shp2 phosphatase regulation, 40–41
 - signaling adaptor recruitment, 37–38
 - STAT dimerization mediation, 31
 - tyrosine kinase target identification, 22–23
- SH3 domain
 - Crk signaling complex assembly, 38
 - overview, 9
 - receptor tyrosine kinase adapter proteins, 9, 31
 - tyrosine kinase target identification, 23
- Shc, platelet-derived growth factor receptor binding, 210
- SHIP proteins, insulin action modulation, 416
- SHP1, Kit regulation, 216
- Shp2
 - mutation in disease, 42–43
 - phosphatase regulation by SH2 domains, 40–41
- SLE. *See* Systemic lupus erythematosus
- SOCS. *See* Suppressor of cytokine signaling
- Sorting. *See* Endosomal sorting, receptor tyrosine kinases
- Sprouty, 141
- STAM, endosomal sorting role, 85–86
- STAT
 - SH2 domain proteins in dimerization mediation, 31
 - STAT3 in MET signaling, 438
 - TAM receptor signaling, 371
- Stem cell factor receptor. *See* Kit

Index

Suppressor of cytokine signaling (SOCS), insulin action modulation, 416
Systemic lupus erythematosus (SLE), TAM receptor defects, 375, 377

T

TACE. *See* ADAM17

TAM receptors

apoptotic cell clearance role, 373–374
autoimmune disease defects, 375–377
cancer role, 378–379
innate immunity role, 374–376
knockout mice, 374–375
overview of types and functions, 369–370
prospects for study, 379
signaling, 371–373
structures, 370–371
vasculature system regulation, 379
virus entry factors, 377–378

Tetraspanins, ADAM shedding control, 122–123

Thyroid cancer. *See* Medullary thyroid carcinoma;
Papillary thyroid carcinoma

Tie1

intracellular domain cleavage by γ -secretase, 54
knockout mouse, 392
ligands, 391

Tie2

functional overview, 287–288
kinase domain structure and signaling, 291–292
knockout mouse, 392
ligands, 391
ligands

angiopoietin recognition studies, 290–291
types, 288–289

structure, 289–290

Tie1 role in signaling, 292–293

Tie-like receptor tyrosine kinase, *Drosophila* studies, 356

Torso, role in anterior/posterior patterning
and metamorphosis, 339–340

Trb3, insulin action modulation, 416

TrkA

endosomal signaling, 105
endosomal sorting, 87
nuclear localization in liver, 70–71

Tyros3. *See* TAM receptors

U

Unfolded protein response (UPR), insulin resistance role, 422

UPR. *See* Unfolded protein response

Usp8, endosomal sorting role, 86

V

Vascular endothelial growth factor receptor (VEGFR)

angiogenesis role

development, 388–389, 391–392

lymphedema defects, 395

tumor angiogenesis, 393–394

coreceptor-modulated sorting of ligand–receptor complexes, 103

cross talk, 234

endocytosis, 80, 99–101

endoplasmic reticulum in signaling modulation, 108

functional overview

sFlt-1, 231–232

VEGFR1, 229

VEGFR2, 230

VEGFR3, 230–231

gene therapy, 236

history of study, 227–228

inhibitor therapy

antibody blockade, 398–399

ligand inhibitors, 397–398

overview, 396

tyrosine kinase inhibitors, 396–397

intracellular domain cleavage by γ -secretase, 54

nuclear trafficking, 59

overview, 227–229

phylogenetic development, 234

signal transduction, 232–234

structure, 229

therapeutic applications, 394–395

therapeutic targeting, 234–236

types and ligands, 389–390

VEGFR2 nuclear function, 73

VEGFR. *See* Vascular endothelial growth factor receptor

v-Src, oncogenesis, 43

W

Wnt

Derailed mediation, 330–332, 351–352

receptors, 325–326

Ror mediation, 329–330

Ryk activation, 70, 330–332

vascular endothelial growth factor receptor signaling cross talk, 234

Z

Zap-70, SH2 domain, 33

ZEB1, 141